Reduced response to regadenoson with increased weight: An artificial intelligence-based quantitative myocardial perfusion study.

Journal: Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
PMID:

Abstract

BACKGROUND: There is conflicting evidence regarding the response to a fixed dose of regadenoson in patients with high body weight. The aim of this study was to evaluate the effectiveness of regadenoson in patients with varying body weights using novel quantitative cardiovascular magnetic resonance (CMR) perfusion parameters in addition to standard clinical markers.

Authors

  • Emmanouil Androulakis
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Georgios Georgiopoulos
    School of Biomedical Engineering and Imaging Sciences, Kings College London, London, UK.
  • Alessia Azzu
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Elena Surkova
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Adam Bakula
    Department of Nuclear Medicine, Cardiac Imaging, University and University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland. Electronic address: adam.bakula@usz.ch.
  • Panagiotis Papagkikas
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Alexandros Briasoulis
    Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
  • Ranil De Silva
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
  • Peter Kellman
    National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (H.X., P.K.).
  • Dudley Pennell
    Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
  • Francisco Alpendurada
    CMR Unit, Royal Brompton Hospital, Guy's and St Thomas's NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.